Neurology
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Figures Only
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Correspondence:
Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when Correspondence are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Frucht, S. J.
Right arrow Articles by Fahn, S.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Frucht, S. J.
Right arrow Articles by Fahn, S.
Related Collections
Right arrow MRS
Right arrow All Pediatric
Right arrow Developmental disorders
Right arrow Mental retardation
Right arrow Antiepileptic drugs
Neurology 2001;57:1112-1114
© 2001 American Academy of Neurology
Brief Communications

A pilot tolerability and efficacy study of levetiracetam in patients with chronic myoclonus

Steven J. Frucht, MD, Elan D. Louis, MD MS;, Cathy Chuang, MD and Stanley Fahn, MD

From the Department of Neurology (Drs. Frucht, Louis, Chuang, and Fahn) and the Gertrude H. Sergievsky Center (Dr. Louis), College of Physicians and Surgeons, Columbia University, New York, NY.

Address correspondence and reprint requests to Dr. Steven J. Frucht, The Neurological Institute, 710 West 168th Street, New York, NY 10032; e-mail: sf216{at}columbia.edu

Levetiracetam was recently approved as adjunctive therapy for partial onset seizures. The authors conducted an open-label trial of levetiracetam in eight patients with chronic myoclonus. Patients were assessed by using the Unified Myoclonus Rating Scale. Levetiracetam was well tolerated. Three of five patients with cortical myoclonus experienced reductions in their myoclonus scores, providing support for a larger, placebo-controlled trial in cortical myoclonus. ;•••>




This article has been cited by other articles:


Home page
 Am J Health Syst PharmHome page
M. U. Farooq, A. Bhatt, A. Majid, R. Gupta, A. Khasnis, and M. Y. Kassab
Levetiracetam for managing neurologic and psychiatric disorders
Am. J. Health Syst. Pharm., March 15, 2009; 66(6): 541 - 561.
[Abstract] [Full Text] [PDF]

Home page
 NeurologyHome page
S. Noachtar, E. Andermann, P. Meyvisch, F. Andermann, W. B. Gough, J. Schiemann-Delgado, and For the N166 Levetiracetam Study Group
Levetiracetam for the treatment of idiopathic generalized epilepsy with myoclonic seizures
Neurology, February 19, 2008; 70(8): 607 - 616.
[Abstract] [Full Text] [PDF]

Home page
 J Child NeurolHome page
F. Vigevano
Topical Review: Levetiracetam in Pediatrics
J Child Neurol, February 1, 2005; 20(2): 87 - 93.
[Abstract] [PDF]

Home page
 NeurologyHome page
S. J. Ruegg, A. J. Steck, and P. Fuhr
Levetiracetam improves paroxysmal symptoms in a patient with stiff-person syndrome
Neurology, January 27, 2004; 62(2): 338 - 338.
[Full Text] [PDF]

Home page
 NeurologyHome page
P. Kinrions, N. Ibrahim, K. Murphy, A.-E. Lehesjoki, I. Jarvela, and N. Delanty
Efficacy of levetiracetam in a patient with Unverricht-Lundborg progressive myoclonic epilepsy
Neurology, April 22, 2003; 60(8): 1394 - 1395.
[Full Text] [PDF]

Home page
 J. Neurol. Neurosurg. PsychiatryHome page
S C Keswani, E H Kossoff, G L Krauss, and C Hagerty
Amelioration of spinal myoclonus with levetiracetam
J. Neurol. Neurosurg. Psychiatry, October 1, 2002; 73(4): 457 - 458.
[Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2001 by AAN Enterprises, Inc.